DRTS

MDSAP Certification Achievement: Alpha Tau Medical Ltd. has received MDSAP certification for its manufacturing facility in Jerusalem, enhancing its commitment to quality and regulatory compliance while facilitating the global expansion of its alpha-radiation cancer therapy, Alpha DaRT.

Alpha DaRT Technology Overview: The Alpha DaRT therapy is designed for targeted treatment of solid tumors through intratumoral delivery of radium-224, aiming to effectively destroy tumor cells while minimizing damage to surrounding healthy tissue.

Alpha DaRT Clinical Trials: Positive interim results from multiple clinical trials of Alpha DaRT for pancreatic cancer and head and neck squamous cell carcinoma show high disease control rates, improved overall survival compared to historical benchmarks, and strong safety profiles.

Regulatory Approvals: The FDA has granted an Investigational Device Exemption for a U.S. pilot study combining Alpha DaRT with chemotherapy for metastatic pancreatic cancer, while France's Ministry of Health approved a multicenter trial using Alpha DaRT alongside capecitabine for locally advanced pancreatic cancer.

Alpha Tau Medical Announcement: Alpha Tau Medical Ltd. has had an abstract accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, focusing on their alpha-radiation therapy, Alpha DaRT, for pancreatic cancer.

R&D Update Day: The company will host an R&D Update Day to discuss new data from their clinical trials, including findings related to the safety and efficacy of Alpha DaRT in treating various cancers.

Board Appointment: Alpha Tau Medical Ltd. has appointed Ms. Maya Netser to its Board of Directors following the Annual General Meeting, while Mr. Meir Jakobsohn completes his term but will continue as an advisor.

Company Overview: Alpha Tau specializes in innovative cancer therapies, particularly the Alpha DaRT technology for treating solid tumors, aiming to enhance patient care through targeted alpha-radiation treatment.

Stock Ratings Update: REV Group Inc. and Alpha Tau Medical Ltd. have seen their ratings improve according to Kenneth Fisher's investment strategy, with REV Group increasing from 50% to 70% and Alpha Tau from 48% to 60%, indicating a more favorable outlook based on their fundamentals and valuations.

Company Descriptions: REV Group specializes in manufacturing specialty vehicles for public services and recreational use, while Alpha Tau Medical focuses on developing radiation therapy technology for cancer treatment, highlighting the diverse sectors these companies operate within.

Corporate Presentation Announcement: Alpha Tau Medical Ltd. will present an overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on January 16, 2025, in San Francisco, with CEO Uzi Sofer and CFO Raphi Levy hosting institutional investor meetings.

About Alpha DaRT Technology: Alpha DaRT is a novel cancer therapy that utilizes alpha-radiation for the treatment of solid tumors, aiming to effectively target tumors while minimizing damage to surrounding healthy tissue.

Company Presentation Announcement: Alpha Tau Medical Ltd. will have CFO Raphi Levy present at the Ladenburg Oncology Innovators & Investors Symposium on December 12, 2024, from 11:00 AM to 11:25 AM EST in a virtual format.

About Alpha Tau and Alpha DaRT: Founded in 2016, Alpha Tau specializes in developing the Alpha DaRT therapy, which utilizes alpha-radiation for treating solid tumors while minimizing damage to surrounding healthy tissue.

FDA Acceptance and Clinical Trials: Alpha DaRT® has been accepted into the FDA's Total Product Life Cycle Advisory Program to expedite market access for treating recurrent glioblastoma multiforme. Additionally, the first patient was treated in a lung cancer study in Israel, and an Investigational Device Exemption was approved for a multi-center study on recurrent cutaneous squamous cell carcinoma.

Financial Overview: Alpha Tau Medical reported a cash balance of $68.4 million as of September 30, 2024, sufficient to fund operations for at least two years, despite a net loss of $22.3 million for the nine months ending September 30, 2024.

Real-time Trading Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them stay updated with real-time news alerts.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.

FDA Acceptance into TAP Program: Alpha Tau Medical Ltd. has been accepted into the FDA's Total Product Life Cycle Advisory Program to expedite market access for its cancer therapy, Alpha DaRT, aimed at treating recurrent glioblastoma multiforme.

Alpha DaRT Technology Overview: Alpha DaRT utilizes alpha-emitters for targeted radiation therapy, designed to effectively destroy solid tumors while minimizing damage to surrounding healthy tissue.

Real-time Trading Intelligence: Benzinga Pro offers the fastest news alerts and real-time intelligence for traders to enhance their market performance.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate stock market insights.

First Patient Treated with Alpha DaRT: Alpha Tau Medical Ltd. has successfully treated its first patient with recurrent lung cancer using its innovative alpha-radiation therapy, Alpha DaRT, in a clinical trial at Hadassah Medical Center in Jerusalem. The trial aims to assess the safety and efficacy of this treatment for patients with tumors in the mediastinum area.

Significance of Alpha DaRT Technology: The use of Alpha DaRT represents a novel approach to targeting tumor cells while minimizing damage to surrounding healthy tissues, particularly important for lung cancer patients who have limited treatment options due to the proximity of vital organs.

Upcoming Conferences: Alpha Tau Medical's CFO, Raphi Levy, will present at several upcoming investment conferences in September and October 2024, including the H.C. Wainwright Annual Global Investment Conference and the Sidoti Virtual Investor Conference.

About Alpha DaRT: Alpha Tau Medical specializes in developing the Alpha DaRT therapy for treating solid tumors, utilizing a unique method of delivering alpha radiation directly to tumors while minimizing damage to surrounding healthy tissue.

Alpha Tau Medical Q2 2024 Earnings: Alpha Tau Medical reported a second-quarter earnings per share of -11 cents, surpassing the analyst estimate of -12 cents, but did not generate any revenue for the quarter.

InvestorPlace Earnings Automation: InvestorPlace Earnings utilizes TradeSmith data to automate the coverage of quarterly earnings reports, providing quick insights on key financial metrics without human intervention.

Conference Announcement: Sidoti Events, LLC has announced the schedule and links for its two-day Small-Cap Conference on September 18-19, 2024, with updates available on their website.

Company Background: Sidoti & Company, LLC formed Sidoti Events, LLC to enhance its conference offerings, leveraging 25 years of experience in small and microcap securities research and maintaining strong connections with institutional investors.